Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Integrated Characterization of AP-2δ Reveals Distinct Regulatory Architecture in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.

Cancers·2026

Same author

Nootkatone as a multi-target modulator of the PD-L1/PD-1 signaling in pancreatic cancer: network pharmacology, docking, molecular dynamics, and DFT analysis.

Naunyn-Schmiedeberg's archives of pharmacology·2026

Same author

Pharmacological evaluation of Lonafarnib in reversing neurobehavioral, neurochemical and metabolic deficit in mouse models of chronic unpredictable mild stress (CUMS).

Metabolic brain disease·2026

Same author

Oxeiptosis - potential in cancer treatment?

Expert reviews in molecular medicine·2026

Same author

AP-2 Transcription Factors as Regulators of Ferroptosis: A Family-Wide Profiling in Diverse Cancer Contexts.

International journal of molecular sciences·2026

Same author

Roburic Acid as a Therapeutic Candidate: Antiproliferative Activity and Secondary Cell Death Response in Colorectal Cancer Cells.

International journal of molecular sciences·2026

Search research articles

Related Experiment Video

Updated: Sep 16, 2025

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts

Published on: June 26, 2018

Anticancer Activity of Roburic Acid: In Vitro and In Silico Investigation.

Adrianna Gielecińska^1,2, Mateusz Kciuk¹, Somdutt Mujwar³

¹Department of Molecular Biotechnology and Genetics, University of Lodz, Banacha 12/16, 90-237 Lodz, Poland.

International Journal of Molecular Sciences

|July 12, 2025

Summary

Roburic acid (RA) shows anticancer potential by inhibiting cancer cell proliferation, particularly in colorectal cancer cells. This natural compound also modulates inflammatory pathways, suggesting it could be a promising scaffold for new cancer therapies.

Keywords:

NF-κB signaling antiproliferative activity colorectal cancer inflammation roburic acid

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

Assessing Specificity of Anticancer Drugs In Vitro

Assessing Specificity of Anticancer Drugs In Vitro

Published on: March 23, 2016

Related Experiment Videos

Last Updated: Sep 16, 2025

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts

Published on: June 26, 2018

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

Assessing Specificity of Anticancer Drugs In Vitro

Assessing Specificity of Anticancer Drugs In Vitro

Published on: March 23, 2016

Area of Science:

Natural product chemistry
Molecular oncology
Pharmacology

Background:

Natural compounds are vital sources of anticancer agents due to their diverse structures and multi-targeted actions.
Roburic acid (RA), a tetracyclic triterpenoid, inhibits NF-κB and MAPK signaling pathways, reduces inflammatory mediators, and impedes cancer progression.

Purpose of the Study:

To evaluate the biological activity of Roburic acid (RA) against various human cancer cell lines and non-malignant cells.
To determine the mechanism of action of RA, distinguishing between cytotoxic and antiproliferative effects.
To investigate RA's potential to modulate pro-tumorigenic signaling pathways.

Main Methods:

Cell viability assays (metabolic activity, trypan blue exclusion, cell density)
Cell proliferation assays (clonogenic assay, BrdU incorporation)
NF-κB reporter assays
In silico interaction studies

Main Results:

RA demonstrated a concentration-dependent inhibition of cancer cell metabolic activity, with higher sensitivity in colorectal cancer cells.
Complementary assays confirmed RA's primary mechanism is antiproliferative, not cytotoxic.
RA attenuated TNF-α-induced NF-κB transcriptional activation, indicating anti-inflammatory properties.
In silico studies predicted RA interactions with proteins involved in proliferation and cell survival (CAII, CES1, EGFR, PLA2G2A).

Conclusions:

Roburic acid (RA) exhibits significant antiproliferative activity against human cancer cell lines, especially colorectal cancer.
RA's ability to inhibit key signaling pathways and inflammatory mediators supports its potential as an anticancer agent.
RA serves as a promising scaffold for developing novel anticancer therapeutics, particularly for colorectal cancer treatment.